Page Menu

Gene Therapy Strategies for Pompe Disease

Dr. Mai Elmallah from the Elmallah Lab (Horae Gene Therapy Center) is conducting research and developing therapeutic strategies for rare inherited diseases such as the Pompe disease

 

What is Pompe Disease?

Pompe disease is a fatal neuromuscular disorder resulting from mutations in the gene for acid alpha-glucosidase (GAA) – an enzyme necessary to degrade lysosomal glycogen.  Infants with Pompe disease suffer from respiratory insufficiency often leading to mechanical ventilation. Unfortunately, the only FDA approved therapy for Pompe disease enzyme replacement therapy (ERT) is suboptimal because it does not cross the blood brain barrier. Therefore, many patients on enzyme replacement therapy still require mechanical ventilation.  In addition, infants and children on ERT eventually develop airway weakness and malacia.

 

▴ Back To Top
▲ Back To Top
Additional Resources
click to open search panel